A five-day rally lifted every major index to fresh highs, Nasdaq led on renewed AI demand, and defense delivered record backlogs. Then a surprise July payroll contraction reset Fed expectations toward a dovish September.
July payrolls unexpectedly contracted by 23,000 against a consensus of +80k. Unemployment ticked down to 4.1%, but the participation and hours worked details skewed dovish. Traders read the print as removing near-term hike risk and pulling forward the first cut.
June CPI cooled to 3.5% YoY headline / 2.6% core, with a –0.4% monthly print. The FOMC held rates unchanged at the July meeting and signaled patience through the September decision, when both July and August CPI will be in hand.
The 10-year settled near 4.68% after briefly probing higher earlier in the week. The 30-year touched multi-year highs in late July, but the soft NFP flattened the front end and eased financial conditions into Friday's close.
Energy led sectors on Aug 7 (+1.48%) as crude firmed on renewed US–Iran tension. Technology (–0.31%) and Financials (–0.33%) gave back a fraction of the week's gains into the print. Dollar softened; gold firmed on the dovish repricing.
| Sector | Weekly Tone | QL Read |
|---|---|---|
| Technology / AI | Leadership | Nvidia +10%+ on the week; Palantir blowout; hyperscaler capex thesis intact |
| Energy | Late-week bid | Crude squeezed higher on geopolitical supply concerns |
| Aerospace & Defense | Constructive | Record backlogs (LMT $230B, RTX $289B) underwrite multi-year revenue visibility |
| Healthcare / Biotech | Mixed | FDA calendar heavy; Moderna's flu PDUFA in focus; single-name volatility elevated |
| Financials | Chop | Rate path uncertainty capped the group; regionals await curve steepening |
| Consumer Discretionary | Mild bid | Rate-cut expectations helped housing-adjacent and travel names |
Blowout Q2. Stock surged ~30% post-print on record commercial AI growth and raised 2026 guidance. US commercial re-accelerated; AIP conversions remain the multiple-defender.
Beat but did not clear the lofty AI-accelerator bar. MI-series ramp commentary was constructive; guide was in-line rather than crushing. Shares whipsawed before firming with the tape.
No print this week, but Nvidia ended the week +10%+ as AI-trade concerns eased and hyperscaler capex commentary from earnings season re-anchored bulls. Momentum factor firmly bid.
Ad-tech and commerce delivered constructive Q2s alongside consumer names (Disney, McDonald's, Airbnb). The demand signal was cleaner than feared on the enterprise side, with AI-driven ad targeting a repeat theme.
Q2 EPS $7.94 on revenue $20.1B (+11% YoY), ahead of $7.23 / $19.37B consensus. FY guide raised to $29.95–$30.65 EPS and $79.75–$81.75B revenue. Backlog swelled to a record $230B (from $193B YE25).
Revenue up 14.5% YoY, beating by ~8%. EPS $1.89 vs $1.66 est. Backlog to a record $289B (+22% YoY), with $43B in new orders — $20B of it in Raytheon defense. Beat-and-raise reset the group multiple.
Near-term catalyst: mRNA-1010 seasonal flu PDUFA on Aug 5. Q1'26 revenue $389M beat consensus by 65%; management held to ~10% FY revenue growth. Oncology pipeline is the multi-year re-rating story; YTD 2026 gain remains one of large-cap biotech's standouts.
Q1'26 revenue $3.61B (+19% YoY), 3.5% ahead. Garetosmab BLA action date and fianlimab melanoma data both land in the August window — meaningful binary catalysts.
Reported into the week alongside a broader pharma cohort. Sector tone remains buoyed by dealmaking and easing policy overhang, with obesity Phase 3 readouts still ahead as the sector's dominant 2H catalyst.
Earlier July action reminded investors that biotech remains binary: MRNA –11%, ImmunityBio and Sarepta –8% in the July rout. Position sizing and event-calendar discipline still matter more than sector beta.